Every data point including side effects and dropout rates weren't in their favor. Further, assuming telapravir gets approved all its data is with Pegasys. I'm not completely sure approval will be a cinch. Either way look for Albuferon to be a commercial flop.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.